Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines

Cancer

Volumn 115, Issue 21, 2009, Pages 4934-4945

  Drozdov, Ignat ^a   Kidd, Mark ^a   Gustafsson, Bjorn I ^a   Svejda, Bernhard ^a,b   Joseph, Richard ^a   Pfragner, Roswitha ^b   Modlin, Irvin M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Bronchopulmonary; Carcinoid; Extracellular signal regulated kinase; Gastrointestinal; H720; H727; KRJ I; Neuroendocrine tumor; Proliferation; Serotonin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; KETANSERIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONDANSETRON; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; TRYPTOPHAN HYDROXYLASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOREGULATION; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOTOXICITY; DNA FLANKING REGION; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG TUMOR; MINIMUM INHIBITORY CONCENTRATION; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMALL INTESTINE TUMOR; TUMOR CELL;

CELL LINE, TUMOR; CELL PROLIFERATION; HOMEOSTASIS; HUMANS; INTESTINAL NEOPLASMS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; KETANSERIN; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEUROENDOCRINE TUMORS; PHOSPHORYLATION; RECEPTORS, SEROTONIN; SEROTONIN; SIGNAL TRANSDUCTION; TRYPTOPHAN;

EID: 70350507208     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24533     Document Type: Article

References (40)

1. Modlin I, Lye K, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959. (Pubitemid 36173145)
2. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol. 2008;20:1-12.
3. Yao J, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
4. Cutz E, Yeger H, Pan J. Pulmonary neuroendocrine cell system in pediatric lung disease-recent advances. Pediatr Dev Pathol. 2007;10:419-435. (Pubitemid 350305238)
5. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil. 2007;19(suppl 2):25-31.
6. Ahlman H, Dahlstrom A, Gronstad K, et al. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin. Ann Surg. 1985;201:81-86.
7. Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996;52:773-794.
8. Eriksson B, Kloppel G, Krenning E, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors - well differentiated jejunal-ileal tumor/ carcinoma. Neuroendocrinology. 2008;87:8-19. (Pubitemid 350308290)
9. Saslow SB, O'Brien MD, Camilleri M, et al. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. Am J Gastroenterol. 1997;92:2250-2256. (Pubitemid 27524311)
10. Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology. 2000;119:1087-1095.
11. Seuwen K, Magnaldo I, Pouyssegur J. Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein. Nature. 1988;335:254-256. (Pubitemid 18224869)
12. Nemecek GM, Coughlin SR, Handley DA, Moskowitz MA. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci U S A. 1986;83:674-678. (Pubitemid 16035536)
13. Westbroek I, van der Plas A, de Rooij KE, Klein-Nulend J, Nijweide PJ. Expression of serotonin receptors in bone. J Biol Chem. 2001;276:28961-28968.
14. Takuwa N, Ganz M, Takuwa Y, Sterzel RB, Rasmussen H. Studies of the mitogenic effect of serotonin in rat renal mesangial cells. Am J Physiol. 1989;257(3 pt 2):F431-F439.
15. Pakala R, Pakala R, Radcliffe JD, Benedict CR. Serotonin-induced endothelial cell proliferation is blocked by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 1999;60:115-123.
16. Leone AM, Errico M, Lin SL, Cowen DS. Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT(1B) receptors in transfected BE-C neuroblastoma cells is inhibited by RGS4. J Neurochem. 2000;75:934-938. (Pubitemid 30660480)
17. Cowen DS. Serotonin and neuronal growth factors - a convergence of signaling pathways. J Neurochem. 2007;101:1161-1171. (Pubitemid 46718809)
18. Gooz M, Gooz P, Luttrell LM, Raymond JR. 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-alpha-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J Biol Chem. 2006;281:21004-21012. (Pubitemid 44115441)
19. Arnold R, Muller H, Schade-Brittinger C, et al; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group [abstract]. J Clin Oncol. 2009;15S. Abstract 4508.
20. Phelps RM, Johnson BE, Ihde DC, et al. NCI-Navy Medical Oncology Branch cell line database. J Cell Biochem. 1996;24(suppl):32-91. (Pubitemid 26277220)
21. Pfragner R, Wirnsberger G, Niederle B, et al. Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): characterization and effects of 5-azacytidine on proliferation Int J Oncol. 1996;8:513-520.
22. Kidd M, Eick G, Modlin I, Pfragner R, Champaneria M, Murren J. Further delineation of the continuous human neoplastic enterochromaffin (EC) cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin. J Mol Endocrinol. 2007;38:181-192.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63. (Pubitemid 14203433)
24. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer. 2005;103:229-236.
25. Kidd M, Nadler B, Mane SM, et al. GeneChip, geNorm, and gastrointestinal tumors: novel reference genes for realtime PCR. Physiol Genomics. 2007;30:363-370. (Pubitemid 47296195)
26. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes [serial online]. Genome Biol. 2002;3:RESEARCH0034.
27. Kidd M, Drozdov I, Joseph R, Pfragner R, Culler M, Modlin I. Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer. 2008;113:690-700.
28. Kidd M, Schally AV, Pfragner R, Malfertheiner MV, Modlin IM. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors. Cancer. 2008;112:1404-1414.
29. Siddiqui EJ, Shabbir M, Mikhailidis DP, Thompson CS, Mumtaz FH. The role of serotonin (5-hydroxytryptamine 1A and 1B) receptors in prostate cancer cell proliferation. J Urol. 2006;176(4 pt 1):1648-1653. (Pubitemid 44307246)
30. Sonier B, Arseneault M, Lavigne C, Ouellette RJ, Vaillancourt C. The 5-HT2A serotoninergic receptor is expressed in the MCF-7 human breast cancer cell line and reveals a mitogenic effect of serotonin. Biochem Biophys Res Commun. 2006;343:1053-1059.
31. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770-776. (Pubitemid 30091095)
32. Kema IP, Schellings AM, Hoppenbrouwers CJ, Rutgers HM, de Vries EG, Muskiet FA. High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. Clin Chim Acta. 1993;221:143-158.
33. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459-465.
34. McCormick F. Activators and effectors of ras p21 proteins. Curr Opin Genet Dev. 1994;4:71-76. (Pubitemid 24060298)
35. Hui L, Bakiri L, Mairhorfer A, et al. p38 Alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet. 2007;39:741-749. (Pubitemid 46848584)
36. Werry TD, Gregory KJ, Sexton PM, Christopoulos A. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem. 2005;93:1603-1615. (Pubitemid 40853284)
37. Watts SW. Activation of the mitogen-activated protein kinase pathway via the 5-HT2A receptor. Ann N Y Acad Sci. 1998;861:162-168. (Pubitemid 29047713)
38. Lee HJ, Ban JY, Seong YH. Blockade of 5-HT receptor with MDL7222 and Y25130 reduces hydrogen peroxide-induced neurotoxicity in cultured rat cortical cells. Life Sci. 2005;78:294-300. (Pubitemid 41570200)
39. Tabatabaie T, Goyal RN, Blank CL, Dryhurst G. Further insights into the molecular mechanisms of action of the serotonergic neurotoxin 5,7-dihydroxytryptamine. J Med Chem. 1993;36:229-236. (Pubitemid 23060090)
40. Walther DJ, Peter JU, Bader M. 7-Hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin-producing tumors. Cancer. 2002;94:3135-3140. (Pubitemid 34670496)